Market Overview

Tickers

Articles

Keywords

Search by keyword...
googlecse

From Earlier: Exelixis Announces Cabozantinib Demonstrates Evidence of Anti-Tumor Effects in Heavily Pretreated Patients with Hepatocellular Carcinoma

Eddie Staley, Benzinga Staff Writer
June 04, 2012 8:12 AM
+ Follow
Print
Email
Tickers: EXEL
Benzinga Share:

Exelixis, Inc. (NASDAQ: EXEL) yesterday reported positive updated interim data from the cohort of hepatocellular carcinoma (HCC) patients participating in the ongoing phase 2 randomized discontinuation trial (RDT) of cabozantinib.

(c) 2013 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.

Posted in: News, FDA

 

Around the Web, We're Loving...

Bush Attorney General: It Was Jihad
EPA's Dirty Secret About The Enviroment
Is Apple's historic run over?

Most Popular

Legendary VC Paul Graham Suspects Bitcoin Was Created by a Government
Earnings Expectations for the Week of April 22
Google Drive Outage Shows Why the Cloud Can't Replace Everything
Barron's Recap: Bulls Run Rampant
What Should You Do with Apple at Current Levels?
UPDATE: Deutsche Bank Downgrades Magnum Hunter Resources to Hold on Updated Q1 Expectations

Related Articles (EXEL)

A Peek Into The Market Before The Trading Starts
Exelixis, Swedish Orphan Biovitrum Enter Three-Year Agreement for Distribution and Commercialization of COMETRIQ for MTC in EU

Partner Network

Get Benzinga's News Delivered Free

Posts by Eddie Staley

Benzinga Professional

Subscribe